2022  1,200
2021  1,540
2020  1,374
2019  1,023
2018  0,932
2017  0,977
2016  0,799
2015  0,662
2014  0,740
2013  0,739
2012  0,637
2011  0,658
2010  0,654
2009  0,570
2008  0,849
2007  0,805
2006  0,330
2005  0,435
2004  0,623
2003  0,567
2002  0,641
2001  0,490
2000  0,477
1999  0,762
1998  0,785
1997  0,507
1996  0,518
1995  0,502
Vol 58(2024) N 2 p. 216-232; DOI 10.1134/S0026893324020158 Full Text

T. Turan1, B. Özaydin2,3, O.H. Emmez2, A.M. Kaymaz2, I.I. Gönül4, M. Bozkurt5, A. Gönenç1*

Angiotensin II Type I Receptor-168A/G Polymorphism Is Associated with Increased the Risk of Glioma in Turkish Population

1Department of Biochemistry, Faculty of Pharmacy, Gazi University, Ankara, 06330 Turkey
2Department of Neurosurgery, Faculty of Medicine, Gazi University, Ankara, 06500 Turkey
3Department of Neurological Surgery, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, 8660 USA
4Department of Medical Pathology, Faculty of Medicine, Gazi University, Ankara, 06500 Turkey
5Department of Neurosurgery, Faculty of Medicine, Istanbul Arel University, Istanbul, 34537 Turkey

Received - 2023-04-04; Revised - 2023-06-02; Accepted - 2023-06-23

Gliomas are the most common primary tumors of the Central Nervous System. Despite advances in the elucidation of molecular pathogenesis, gliomas still remain incurable. In the study, it was aimed to investigate the possible connection between ACE and AGTR1 polymorphisms with glioma pathogenesis and also the relationship of some angiogenic markers with gliomagenesis. In this respect, 96 glioma patients and 104 healthy controls were included in the study. To determine the effect of genetic polymorphisms on the predisposition of diffuse infiltrative glial tumors in the Turkish population, angiotensin-converting enzyme gene (ACE) insertion/deletion, angiotensin II receptor type 1 gene (AGTR1) -168A/G, -535C/T, -825T/A, and Vascular Endothelial Growth Factor gene (VEGF) +936C/T, -2578C/A polymorphisms were investigated by PCR-RFLP. Allele/genotype frequencies between patients and controls were determined. Besides, relative gene expressions of ACE, AGTR1, and VEGF were detected by real time-PCR, while ACE, VEGF, ET-1, eNOS, and NO levels were measured in both serum and tissue by ELISA. In AGTR1 -168A/G polymorphism, the risk of glioma in the AA genotype decreased, while increased by 2.27 times in the G allele. Allele frequency and genotype distributions of other polymorphisms were found similar between two groups. Serum levels of ACE, VEGF, eNOS, NO, and tissue levels of ACE, ET-1, eNOS, NO were also different between the patients and controls. ACE, AGTR1, and VEGF expressions in patient group were found significantly higher than in control one. These results provide the first evidence linking -168A/G polymorphism in AGTR1 gene with glioma risk in the Turkish population.

glioma, angiogenesis, ACE, AGTR1, polymorphism